Ten percent of breast cancers are ER/progesterone receptor (PR)-positive and human epidermal growth factor receptor 2 (HER2)-positive, 69% are ER/PR-positive and HER2-negative, 7% are ER/PR-negative and HER2-positive, and the remaining 13% are classified as triple-negative [25,26]. This evidence concerns the gene ERBB2 and breast carcinoma.